Serous Tubal Intraepithelial Carcinoma After Neoadjuvant Chemotherapy: A Report of 2 Cases.

Autor:	Stroot IAS; Department of Gynecologic Oncology.; Department of Epidemiology., Smit L; Department of Gynecologic Oncology., de Bock GH; Department of Epidemiology., Wagner MM; Department of Gynecologic Oncology., Jalving M; Department of Medical Oncology., van Kempen LCLT; Department of Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.; Department of Pathology, Antwerp University Hospital, University of Antwerp, Edegem, Belgium., Bart J; Department of Pathology and Medical Biology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands., Mourits MJE; Department of Gynecologic Oncology.
Jazyk:	angličtina
Zdroj:	International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists [Int J Gynecol Pathol] 2025 Jan 01; Vol. 44 (1), pp. 94-97. Date of Electronic Publication: 2024 Aug 22.
DOI:	10.1097/PGP.0000000000001045
Abstrakt:	Serous tubal intraepithelial carcinoma (STIC) is regarded as the origin of most high-grade serous carcinomas (HGSC). After a diagnosis of isolated STIC, risk of developing HGSC is substantial. Since surveillance cannot detect HGSC in time to cure the disease, there is no consensus on the optimal treatment after a diagnosis of isolated STIC, but chemotherapy is considered one of the possible strategies. In this case report, we describe 2 women with advanced-stage HGSC treated with 3 cycles of neoadjuvant chemotherapy followed by interval debulking surgery. In both women, histopathological examination showed a complete histopathological tumor response, but a vital STIC was found in both cases. The 2 cases presented here indicate that STICs may not respond to chemotherapy. Further research focused on the underlying biology and chemosensitivity of STIC, as well as the effectiveness of treatment to prevent HGSC in case of isolated STIC, is needed. Competing Interests: L.C.L.T.v.K.: Grants from Amgen, AstraZeneca, Bayer, Janssen-Cilag, Merck, NanoString, Roche, Servier. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Janssen, NanoString, Novartis, Pfizer, and Roche. Support provided for attending meetings and/or travel from Roche, NanoString, and ThermoFisher. Advisory Board from Cyclomics, Janssen-Cilag, LOGEX, Merck, Menarini, Protyon, Roche. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from EORTC Melanoma Group, Commission Personalized Medicine – Belgium. Stock from Cyclomics. Receipt of equipment, materials, drugs, medical writing, gifts, or other services from LOGEX, Lynxcare, and NanoString. All are not related to this manuscript. J.B.: Grants from Dutch Cancer Society, AstraZeneca. All are not related to this manuscript. M.J.: Advisory board of Pierre Fabre. All are not related to this manuscript. The remaining authors declare no conflicts of interest. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu